Syndax Announces New Data from Secondary Analysis of the …
13 hours ago · Niktimvo (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior ...
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ …
Aug 14, 2024 · Niktimvo (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and …
Syndax Announces New Data from Secondary Analysis of the
13 hours ago · --Syndax Pharmaceuticals, today announced that multiple abstracts evaluating Niktimvo™, an anti-CSF-1R antibody for the treatment of chronic graft-versus-host disease, have been accepted for ...
FDA approves axatilimab-csfr for chronic graft-versus-host disease
On August 14, 2024, the Food and Drug Administration approved axatilimab-csfr (Niktimvo, Incyte Corporation), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of...
Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 …
2 days ago · About Niktimvo TM (axatilimab-csfr) Niktimvo (axatilimab-csfr) is a first-in-class anti-CSF-1R antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ …
Aug 14, 2024 · Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD. Pivotal data from the AGAVE-201 study supporting...
Syndax Announces New Data from Secondary Analysis of the
1 day ago · Niktimvo™ (axatilimab-csfr) can cause infusion-related reactions. Infusion-related reactions, including hypersensitivity reactions, occurred in 18% of patients who received Niktimvo in the clinical trial (AGAVE-201), with Grade 3 or 4 reactions in 1.3%. ... BioSpace is the digital hub for life science news and jobs. We provide essential ...
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft …
Aug 15, 2024 · On Wednesday, the FDA approved Incyte Corporation (NASDAQ: INCY) and Syndax Pharmaceuticals Inc’s (NASDAQ: SNDX) Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody for chronic graft-versus-host...
FDA approves Incyte's treatment for chronic graft-versus-host …
Aug 14, 2024 · Niktimvo, co-developed with Syndax Pharmaceuticals (SNDX.O), is approved for use in adult and pediatric chronic GvHD patients, weighing at least 40 kg, after the failure of at least two prior...
Incyte builds GvHD presence with Niktimvo approval
Aug 15, 2024 · FDA clears Incyte's potential blockbuster Niktimvo as a treatment for chronic GvHD, making it a companion to the company's Jakafi for the disorder.